GenusPlus is flying under the radar here.FY22 - $295M revenues...

GenusPlus is flying under the radar here.

1. FY22 - $295M revenues locked in & a tender pipeline of $344M in FY22. Management have stated they expect FY22 revenues to be circa $400M which equates to receiving around 1/3 of the FY22 pipeline. This may be under or over but management appear to be quite conservative.
2. Revenues have grown YOY with a CAGR of 127% from FY18-FY21. Current valuation lets me buy this growth in revs for 0.5x
   3. Net Income has also grown YOY in-line with revenues at a CAGR of 128% even with some slight dilution. Current valuation lets me buy this growth for 12x
   

4. SG&A margins have been declining approx. 4.3% YOY which is great to see also.

5. Return ratios have also been very impressive with ROE averaging 28.5% & ROIC averaging 18.4%